against viral epitopes to analyze different variables which could be critical during the epitope-specific stimulation period. Two parameters were found to greatly enhance detection sensitivity (i.e., to specifically increase epitope-driven signal while keeping background noise to a minimum): use of human serum-free vs. serum-supplemented culture medium (2.4-fold median increase) and
Introduction
Detection and quantification of antigen-specific T cell responses has represented a milestone advance in the immunology field. Not only it has allowed to address fundamental questions about the dynamics of T cell responses, but it has also offered key clinical applications for infectious, tumoral and autoimmune diseases.
Of the two T cell arms of adaptive immunity, CD8 T cells have received more attention due to their well established role in mounting + immune responses against viral and cancerous threats. Not denying the contribution of CD4 T cells in these settings ( + Perez-Diez et al.,
), progress with their study has lagged behind due to several technical limitations, including more scattered HLA Class II distribution 2007 ( ), more difficult epitope identification ( ), troublesome HLA Class II tetramer production ( Nepom, 1995 Kwok et al., 2001 Mallone and ) and lower Ag-specific T cell frequencies ( ). Furthermore, more recent studies in type 1 diabetes (T1D) ( Nepom, 2004 Homann et al., 2001 ; ; ) and multiple sclerosis ( ) have highlighted the Amrani et al., 2000 Toma et al., 2005 Mallone et al., 2007 Crawford et al., 2004 fundamental contribution of CD8 T cells in autoimmunity ( ; ), thus challenging the et al., 2002 Walter and Santamaria, 2005 paradigm depicting these diseases as predominantly CD4 T helper 1 mediated.
+ -
Among the various techniques which can be used to detect CD8 T cell responses, two main strategies share the mainstream. On one ELISpot-based techniques give an indirect detection of Ag-specific T cells by means of their cytokine (mostly IFN-) secretion, but are γ endowed with at least a 10-fold higher sensitivity, as they can detect as few as 0.001 Ag-specific cells ( ).
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The detection sensitivity reached by ELISpot is particularly useful in the autoimmune context, since autoreactive T cell responses are typically of much lower grade (i.e., lower intensity and precursor frequency) than those found in the viral and tumor setting (Mallone and ) . For example, our recent ELISpot studies on T1D patients vs. healthy controls indicate that the -cell epitope-specific CD8 Nepom, 2005 of current ELISpot protocols is therefore highly needed to maximize the chances of detecting such rare events and to eventually reach clinical application. Such optimization should aim at obtaining the highest specific signal, while keeping the background noise of the system to a minimum. We here address this issue by considering different costimulatory parameters during the ELISpot culture incubation, in order to achieve preferential amplification of the epitope-specific T cell responses.
Materials and methods
Study subjects
Eight HLA-A2 (HLA-A 0201) healthy donors ( ) were selected by FACS screening of lysed whole blood with the + * Table I anti-HLA-A2 mAb BB7.2. Subsequent genotyping was performed using the Olerup SSP HLA 02 kit (GenoVision/Qiagen, Vienna, * Austria). All subjects gave written informed consent and the study was approved by the Local Ethics Committee. PBMCs were isolated by density gradient centrifugation using lymphocyte separation medium (PAA, Les Mureaux, France), and immediately used or stored frozen (10 DMSO in pooled human male AB serum). In selected experiments, immunomagnetically CD4-depleted or CD8-enriched (>90 % % pure) PBMCs were prepared using Miltenyi CD4 positive and CD8 negative selection kits, respectively (Miltenyi Biotech, Paris, France).
To test detection of -cell-specific CD8 T cell responses in T1D vs. healthy subjects, PBMCs were obtained from three adult (29-, 
mAbs, cytokines and culture media
Anti-CD28 mAb (clone CD28.2) was purchased from BD Pharmingen (Le Pont de Claix, France). Recombinant human IL-2 and IL-7 were from R&D Systems (Lille, France). RPMI, AIM-V (both from Invitrogen, Cergy Pontoise, France) or X-VIVO 15 culture medium (BioWhittaker-Lonza, Levallois-Perret, France) were used for ELISpot assays, as specified for each experiment.
ELISpot
Ninety-six well PVDF plates (Millipore, Saint-Quentin-en-Yvelines, France) were coated overnight with an anti-IFN-Ab γ (U-CyTech, Utrecht, The Netherlands). After blocking with RPMI 10 human serum (HS; PAA) for 1 h at 37 C, peptides were + %°d istributed into wells at the suboptimal concentrations (0.5 500 nM) previously determined for each donor, along with the appropriate -co-stimuli, as detailed for each experiment. PBMCs were seeded in triplicates at 3 10 cells/well and cultured for 20 24 h. Following ExtrAvidin and Sigmafast 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) tablets (both from Sigma). Spots were counted using an AID reader (Strassberg, Germany), means of triplicate wells calculated and results expressed as spot-forming cells (SFC)/10 PBMCs after background subtraction. The cut-off for a positive response was set at 3SD above the average basal reactivity (i.e., 6 reactivity against HIV gag and DMSO diluent alone). This was chosen as the cut-off allowing for the best diagnostic sensitivity (i.e., assay is of 14.1 intra-assay, 4.2 at the analytical inter-assay level (i.e., using thawed PBMC samples frozen on the same occasion) and % % 9.2 at the pre-analytical and analytical level (i.e., using separate blood draws from the same donor) ( ). Coefficients of All graphs are displayed as means of triplicate wells SEM. Since spot numbers are normally distributed within each triplicate, ± comparisons of means within the same donor were carried out with two-tailed Student s test, while the non-parametric Wilcoxon matched ' t pairs test was used for comparing two ELISpot conditions across the whole cohort of donors. Analysis of variance (ANOVA) was used for comparisons among multiple groups. <0.05 was considered to be of statistical significance. P
Results
Titration of epitope-specific responses
In order to better visualize the influence of different culture conditions on the ELISpot performance, we preliminarily titrated the reactivity of each donor to one viral epitope chosen among Influenza, CMV or EBV ones, or to a pool of the three (Tab. I). We thus identified for each subject a suboptimal (0.5 500 nM) peptide concentration achieving a positive response but with no more than 100 -SFC/10 PBMCs when tested without cytokine addition and in RPMI 10 HS ( ). As we plate 3 10 PBMCs/well, this 6 + %
Fig. 1A
× 5
corresponds to <30 spots counted in each well before normalization to 10 PBMCs, a number which avoids counting inaccuracies due to 6 excessive spot densities. All experiments ( to ) were subsequently performed with the indicated peptide(s) and suboptimal Fig. 1 5 concentrations specific to each donor (Tab. I).
Culture media
As differences in human serum (HS) batches may affect the reproducibility of the ELISpot technique, we first investigated whether substituting HS-supplemented RPMI with AIM-V medium would improve assay performance. As shown in , AIM-V performed Fig. 1A consistently better than HS-supplemented RPMI, as all but one donor displayed increased responses with this latter culture condition. The median increase in specific signal was of 2.4-fold (range 1 6.4-fold; <0.03 by Wilcoxon test), while background noise was low in all -P instances (<15 SFC/10 PBMCs).
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The lower specific signals obtained with HS-supplemented medium were not due to poor performance of the particular HS batch used, as different lots either produced locally or commercially available gave similar results ( ). However, the absence or presence of -- 
Anti-CD28 costimulation
We next tested the effect of adding an anti-CD28 mAb to the ELISpot culture, as it has previously been reported that such costimulation increases detection sensitivity ( ). However, we did not observe any beneficial effect ( ): addition of Ott et al., 2004 Fig . 2 anti-CD28 mAb (1 g/ml) to AIM-V medium marginally increased signal detection in only 1 of the 4 donors tested (39.7 increase; μ % P= 0.29). This was moreover obtained at the expense of a much higher background. Even in those subjects where the specific signal was not improved, the increase in noise was quite important (median increase 7.3-fold; range 1 13.3; <0.03 by Student s t test for 3 of 4 donors).
IL-2 costimulation
We have previously reported that addition of low dose (0.5 U/ml) IL-2 leads to a small but consistent improvement in ELISpot sensitivity, as assessed by measuring low grade CD8 T cell responses against -cell autoantigens in T1D patients ( ;
Mallone et al., 2007
). This was indeed still the case when HS-supplemented RPMI medium was enriched with low dose IL-2 as per our Blancou et al., 2007 previous protocol to detect viral epitope-specific responses ( ; median signal increase 2.3-fold, range 1.1 3.8; <0.06 by Wilcoxon Fig. 3 -P test). However, when this IL-2 supplement was added to the HS-free AIM-V medium, this improvement was no longer observed ( ). Fig. 4 Rather, a marginal increase in specific signal (median 1.05-fold, range 0.52 1.4-fold; 0.56) was counterbalanced by a larger increase in -P= background noise (median 2.4-fold, range 0.83 3.6-fold; 0.16). These increases were even more important when higher IL-2 doses -P= where used. IL-2 doses lower than 0.5 U/ml did not induce any significant effect as compared to unsupplemented HS-free AIM-V (not shown).
IL-7 costimulation
As IL-7 is thought to be an important co-stimulation factor for memory T cells ( ), we hypothesized that it could Bielekova et al., 1999 also have a more beneficial effect than IL-2 on the ELISpot-detected signal. Indeed, low dose (0.5 ng/ml) IL-7 induced a small yet highly reproducible increase in specific signal, while increasing the basal levels of reactivity only marginally (
). The median increase in Fig. 5A inserm-00266553, version 1 -26 Mar 2008 4 10 net signal was of 50 (range 20 250 ; <0.03 by Wilcoxon test), while background noise was unaffected in most cases (median % -% P increase 0 , range -11 63.9 ; 0.31). Higher IL-7 doses (1 5 ng/ml) only gave a marginal increase in specific signal (median 21.7 and % -% P= -7.6 , respectively; 0.22 and 0.44), while the increase in background level was much higher (median 49.1 and 267.0 ; 0.06 and % P= % P= 0.03). IL-7 supplements lower than 0.5 ng/ml did not have any effect as compared to unsupplemented AIM-V (not shown). The effect of low dose IL-7 was exerted on CD8 T cells, as it was still present when CD4-depleted PBMCs or purified CD8 cells were used ( ). and IL-7 achieved a synergistic effect, with a 13-fold increase in signal as compared to HS-supplemented RPMI ( <0.04). P HLA-A2 T1D patients and healthy controls were subsequently compared for their responses against immunodominant -cell epitopes + β by using either our previously described protocol (HS-supplemented RPMI IL-2) ( ) or the newly optimized condition with HS-free AIM-V and IL-7 ( ). Such responses were detected in T1D but not in healthy subjects, as previously reported (  Fig. 6B Mallone ). Some rise in the background levels was observed with IL-7-supplemented AIM-V in 4 of 6 cases, but it was overall not et al. responses of healthy subjects did not rise significantly in 91.7 (11/12) of cases, and remained negative in all instances.
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Discussion
We provide evidence that optimized culture and costimulation conditions during ELISpot incubation greatly improve epitope-specific stimulation. Small increases in background levels were outweighed by a much higher increase in specific signal. Two parameters were found to be critical: substitution of HS-supplemented RPMI with HS-free AIM-V medium; and addition of low dose (0.5 ng/ml) IL-7.
The higher efficacy of the AIM-V medium could have been due either to exclusion of HS from the culture condition or to the composition of the AIM-V medium itself. The former hypothesis was excluded, as addition of HS to AIM-V or X-VIVO did not bring a significant change. The latter hypothesis is therefore the most likely, but the proprietary formulation of AIM-V does not allow further speculations. However, excluding HS from the culture media brings the advantage of avoiding lot-to-lot variabilities.
The costimulatory effect of IL-7 was found to be quite selective on the epitope-specific fraction of interest, while only marginally increasing basal reactivity. Other cytokines previously found to increase detection sensitivity such as IL-15 ( ) did not Jennes et al., 2002 have the same effect, as they greatly increased background noise, with little advantage on the net signal revealed (not shown). The advantage of IL-7 vs. IL-2 could be due to a preferential effect on the IL-7 receptor-positive (CD127 ) effector/memory compartment as HS-supplemented RPMI ( ), but much less with HS-free AIM-V due to background increase ( ). The culture medium used Fig. 3 Fig . 4 should therefore be taken into account when titrating costimulatory reagents. Keeping the noise of the system to a minimum is particularly important when looking at low grade T cell responses, as small changes can easily remain undetected over a high background.
The final advantage of this optimized stimulation scheme on the ELISpot detection sensitivity was shown by looking at -cell β epitope-specific CD8 responses in T1D patients vs. healthy controls. While maintaining specificity with regard to disease status, + IL-7-supplemented HS-free AIM-V allowed for a ~35-fold median increase in the magnitude of the -cell epitope-specific responses. Such β an increase is unlikely to solely reflect an expansion of the epitope-specific precursors, given the short (24 h) stimulation period. It probably also reflects increased bystander activation, a mechanism with a much higher potential for amplifying T cell responses. It may be argued that such amplification does not anymore reflect the ex-vivo precursor frequency. However, the main scope of ELISpot techniques in the clinical setting especially in the autoimmunity field is to allow for disease monitoring, i.e., for early diagnosis, prognostic Effect of anti-CD28 costimulation on the epitope-specific T cell responses measured by ELISpot. PBMCs from the indicated donors were tested using HS-free AIM-V medium with or without addition of anti-CD28 mAb (1 g/ml). Effect of IL-2 addition to HS-free AIM-V medium on ELISpot responses. PBMCs from different donors were subjected to ELISpot testing using HS-free AIM-V without IL-2 (black bars) or with 5, 1 or 0.5 U/ml IL-2 (dark grey, light grey and hatched bars, respectively). The superimposed white bars represent background reactivities for each condition, while total bar heights (colored plus white portion) correspond to raw spot counts before basal subtraction, as for . <0.02 for the difference in basal-subtracted responses as compared to the no condition ( <0.03 for the IL-7 0.5 ng/ml vs. no cytokines condition when comparing cumulative data for all donors by Wilcoxon test). P " " **P <0.05 for the difference in background noise as compared to the no cytokine condition ( <0.05 for the IL-7 5 ng/ml and 1 ng/ml vs. no T1D patients (first row) and healthy controls (second row) were assayed against different -cell epitopes using either HS-supplemented + β RPMI containing 0.5 U/ml IL-2 or HS-free AIM-V medium containing 0.5 ng/ml IL-7. 
